Sonnet BioTherapeutics Announces Launch of CEO Corner Platform
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) has launched its CEO Corner platform, featuring Founder and CEO Pankaj Mohan. This new initiative aims to provide in-depth perspectives on press releases, events, corporate updates, and pipeline progress. The platform allows interested parties to ask questions and submit topics for future videos.
Pankaj Mohan emphasized the importance of keeping shareholders well-informed for Sonnet's future success. The CEO Corner is designed to offer a broader perspective on news releases, clinical studies, and other business developments. It serves as an additional channel for direct communication with current and potential stockholders.
The first segment of the CEO Corner is now accessible on the Company's website. Segments will remain available for 90 days after posting. This initiative underscores Sonnet's commitment to transparency and shareholder engagement as they progress with their FHAB platform and focus on growing value for all shareholders.
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) ha lanciato la sua piattaforma CEO Corner, con il Fondatore e CEO Pankaj Mohan. Questa nuova iniziativa mira a fornire prospettive approfondite su comunicati stampa, eventi, aggiornamenti aziendali e progressi del pipeline. La piattaforma permette alle parti interessate di porre domande e inviare argomenti per futuri video.
Pankaj Mohan ha sottolineato l'importanza di tenere gli azionisti ben informati per il futuro successo di Sonnet. Il CEO Corner è progettato per offrire una prospettiva più ampia sui comunicati di notizie, studi clinici e altri sviluppi aziendali. Serve come canale aggiuntivo per una comunicazione diretta con gli attuali e potenziali azionisti.
Il primo segmento del CEO Corner è ora accessibile sul sito web dell'azienda. I segmenti rimarranno disponibili per 90 giorni dopo la pubblicazione. Questa iniziativa sottolinea l'impegno di Sonnet per la trasparenza e il coinvolgimento degli azionisti mentre proseguono con la loro piattaforma FHAB e si concentrano sull'aumento del valore per tutti gli azionisti.
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) ha lanzado su plataforma CEO Corner, con el Fundador y CEO Pankaj Mohan. Esta nueva iniciativa tiene como objetivo proporcionar perspectivas profundas sobre comunicados de prensa, eventos, actualizaciones corporativas y avances en el pipeline. La plataforma permite a las partes interesadas hacer preguntas y enviar temas para futuros videos.
Pankaj Mohan enfatizó la importancia de mantener a los accionistas bien informados para el futuro éxito de Sonnet. El CEO Corner está diseñado para ofrecer una perspectiva más amplia sobre comunicados de noticias, estudios clínicos y otros desarrollos empresariales. Sirve como un canal adicional para comunicaciones directas con los accionistas actuales y potenciales.
El primer segmento del CEO Corner ya está accesible en el sitio web de la compañía. Los segmentos permanecerán disponibles durante 90 días después de su publicación. Esta iniciativa subraya el compromiso de Sonnet con la transparencia y el compromiso de los accionistas mientras avanzan con su plataforma FHAB y se enfocan en aumentar el valor para todos los accionistas.
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN)가 창립자이자 CEO인 Pankaj Mohan과 함께 CEO Corner 플랫폼을 출시했습니다. 이 새로운 이니셔티브는 보도자료, 이벤트, 기업 업데이트 및 파이프라인 진행 상황에 대한 심층적 관점을 제공하는 것을 목표로 합니다. 이 플랫폼은 이해 당사자들이 질문을 하거나 향후 비디오를 위한 주제를 제출할 수 있게 해줍니다.
Pankaj Mohan은 Sonnet의 미래 성공을 위해 주주들에게 잘 알리는 것의 중요성을 강조했습니다. CEO Corner는 뉴스 릴리스, 임상 연구 및 기타 비즈니스 개발에 대한 더 넓은 관점을 제공하기 위해 설계되었습니다. 현재 및 잠재적 주주들과의 직접 커뮤니케이션을 위한 추가 채널 역할을 합니다.
CEO Corner의 첫 번째 세그먼트는 이제 회사의 웹사이트에서 접근 가능합니다. 세그먼트는 게시 후 90일 동안 이용 가능합니다. 이 이니셔티브는 Sonnet이 FHAB 플랫폼을 진행하며 모든 주주를 위한 가치를 증대시키려는 노력을 기울이고 있음을 강조합니다.
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) a lancé sa plateforme CEO Corner, avec le Fondateur et CEO Pankaj Mohan. Cette nouvelle initiative vise à fournir des perspectives approfondies sur les communiqués de presse, les événements, les mises à jour d'entreprise et les progrès du pipeline. La plateforme permet aux parties intéressées de poser des questions et de soumettre des sujets pour de futures vidéos.
Pankaj Mohan a souligné l'importance de tenir les actionnaires bien informés pour le succès futur de Sonnet. Le CEO Corner est conçu pour offrir une perspective plus large sur les nouvelles, les études cliniques et d'autres développements commerciaux. Il sert de canal supplémentaire pour une communication directe avec les actionnaires actuels et potentiels.
Le premier segment du CEO Corner est désormais accessible sur le site web de l'entreprise. Les segments resteront disponibles pendant 90 jours après publication. Cette initiative souligne l'engagement de Sonnet envers la transparence et l'engagement des actionnaires alors qu'ils avancent avec leur plateforme FHAB et se concentrent sur l'augmentation de la valeur pour tous les actionnaires.
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) hat seine CEO Corner-Plattform mit dem Gründer und CEO Pankaj Mohan gestartet. Diese neue Initiative zielt darauf ab, gründliche Perspektiven zu Pressemitteilungen, Veranstaltungen, Unternehmensupdates und Fortschritt im Pipeline zu bieten. Die Plattform ermöglicht es interessierten Parteien, Fragen zu stellen und Themen einzureichen für zukünftige Videos.
Pankaj Mohan betonte die Wichtigkeit, die Aktionäre gut informiert zu halten für den zukünftigen Erfolg von Sonnet. Der CEO Corner ist darauf ausgelegt, eine breitere Perspektive auf Nachrichtenmitteilungen, klinische Studien und andere Unternehmensentwicklungen zu bieten. Er dient als zusätzlicher Kanal für direkte Kommunikation mit aktuellen und potenziellen Aktionären.
Das erste Segment des CEO Corner ist jetzt auf der Webseite des Unternehmens verfügbar. Segmente bleiben für 90 Tage nach der Veröffentlichung zugänglich. Diese Initiative unterstreicht Sonnet's Engagement für Transparenz und Aktionärseinbindung, während sie mit ihrer FHAB-Plattform voranschreiten und darauf konzentriert sind, den Wert für alle Aktionäre zu steigern.
- Launch of CEO Corner platform for enhanced shareholder communication
- Opportunity for investors to ask questions and suggest topics
- Commitment to transparency and shareholder engagement
- None.
CEO Corner segments to include additional discussion related to press releases, events, corporate updates and pipeline progress
Provides interested parties the ability to ask questions and submit topics for future videos
Access the Sonnet CEO Corner here
PRINCETON, NJ, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic drugs, today announced the launch of its CEO Corner platform featuring Pankaj Mohan, Founder and Chief Executive Officer of Sonnet. The CEO Corner platform is intended to provide additional in-depth perspective to press releases, events, corporate updates and development pipeline progress.
“We believe that keeping our shareholders well informed is crucial for the future success of Sonnet and we are committed to executing on that belief,” commented Pankaj Mohan, Founder and Chief Executive Officer of Sonnet. “The CEO Corner is a new, additional way for us to connect directly with both current and potential stockholders. As we move forward with our development pipeline, the CEO Corner segments are intended to offer a broader perspective on news releases, clinical studies, and other business developments. We believe in the future of our FHAB platform and are dedicated to growing value for all shareholders.”
The first segment of the CEO Corner is now accessible on the Company’s website here. Segments on the CEO Corner platform will be accessible on the Company’s website (www.sonnetbio.com) for 90 days.
About Sonnet BioTherapeutics Holdings, Inc.
Sonnet is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single or bifunctional action. Known as FHAB (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and "hitch-hikes" on human serum albumin (HSA) for transport to target tissues. Sonnet's FHAB was designed to specifically target tumor and lymphatic tissue, with an improved therapeutic window for optimizing the safety and efficacy of immune modulating biologic drugs. FHAB is the foundation of a modular, plug-and-play construct for potentiating a range of large molecule therapeutic classes, including cytokines, peptides, antibodies, and vaccines.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the outcome of the Company’s clinical trials, the Company's cash runway, the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.
These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential,” "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
JTC Team, LLC
Jenene Thomas
908.824.0775
SONN@jtcir.com
FAQ
What is the purpose of Sonnet BioTherapeutics' new CEO Corner platform?
How long will CEO Corner segments be available on Sonnet's website?
Can investors interact with Sonnet BioTherapeutics through the CEO Corner platform?
Who is featured in Sonnet BioTherapeutics' CEO Corner videos?
